Dr. Reddy’s launches first generic Hemabate injection
Dr. Reddy’s is launching the first generic of Pfizer's Hemabata (carboprost tromethamine) injection. The generic will be available in a dosage strength of 250 mcg/ml in a 1ml single-dose vial.
“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy by the FDA,” Dr. Reddy’s CEO North America generics, Marc Kikuchi said, adding, “With a CGT designation, we have 180-day CGT exclusivity to market this product.”
The Hemabate brand had a market value of approximately $55 million for the most recent 12 months ending in April 2019, according to IQVIA.
“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy by the FDA,” Dr. Reddy’s CEO North America generics, Marc Kikuchi said, adding, “With a CGT designation, we have 180-day CGT exclusivity to market this product.”
The Hemabate brand had a market value of approximately $55 million for the most recent 12 months ending in April 2019, according to IQVIA.